NCT04227210

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

A Phase 1 Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Meissa Vaccines, Inc. · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.

Conditions

• Respiratory Syncytial Virus Infections

Interventions

Type	Name	Description
BIOLOGICAL	RSV vaccine MV-012-968 (dosage #1)	Single dose administered intranasally on Day 1
BIOLOGICAL	RSV vaccine MV-012-968 (dosage #2)	Single dose administered intranasally on Day 1

Timeline

• Start date: 2020-01-14
• Primary completion: 2020-08-27
• Completion: 2020-08-27
• First posted: 2020-01-13
• Last updated: 2020-09-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study